Lymphogranuloma venereum (LGV) is a sexually transmitted infection (STI) caused by the L1, L2, and L3 serovars of *Chlamydia trachomatis* (CT). An LGV outbreak among men who have sex with men (MSM) first reported in the Netherlands in 2003 has since spread across other industrialized countries ([@R1]). Cases are typically seen among white, HIV-positive MSM who report unprotected anal intercourse, other high-risk behaviors, and STI co-infection and who commonly have symptoms of proctitis (i.e., rectal pain, rectal discharge, bloody stools, constipation, and tenesmus) ([@R2]).

The United Kingdom now has the largest documented outbreak of LGV among MSM worldwide ([@R3]*,*[@R4]). Infection control in England has relied on CT DNA typing and treatment of symptomatic MSM who have CT-positive rectal infections and their contacts, as well as health promotion. These measures were supported by a large prospective study in the United Kingdom during 2006--2007 that reported \<6% of LGV CT infections were asymptomatic ([@R5]). However, studies in the Netherlands and Germany, and a smaller UK study, have reported higher proportions (17%--53%) of asymptomatic infection ([@R6]--[@R8]). We reinvestigated the prevalence of asymptomatic LGV CT infection among MSM in the United Kingdom to assess whether it may be sustaining the current epidemic.

The Study
=========

In the UK, STI clinics are open access and provide free testing and treatment. Regular STI and HIV screening is encouraged for sexually active MSM with or without symptoms ([@R9]). A full medical and sexual history are recorded for all patients, and a physical examination is done for those with symptoms.

Twelve UK STI clinics participated; all serve cities with large MSM populations and routinely screen MSM for CT by examining urine or swab samples of the pharynx, urethra, and rectum (either clinician-obtained or self-taken) according to UK guidelines ([@R10]). All MSM tested for CT during September 24--December 7, 2012, were included except those who had received antibiotic drugs during the previous 6 weeks.

More than 10,000 CT tests were performed during the study period. Local laboratories performed routine testing for CT and referred all positive specimens from study participants to the Sexually Transmitted Bacteria Reference Unit of the national reference laboratory in London to test for LGV. At the reference laboratory, all specimens underwent extraction by using the Roche MagNA Pure LC extractor (Roche Diagnostics, Indianapolis, IN, USA), then CT confirmation by using a plasmid targeted real-time PCR and an LGV-specific real-time PCR targeting the *pmpH* deletion on the RotorGene (QIAGEN, Valencia, CA, USA). Details of the LGV reference service were previously published ([@R11]).

Clinical data for symptoms were submitted for all study participants to Public Health England (PHE) through a secure web portal ([Technical Appendix](#SD1){ref-type="local-data"} Figure). Patients reporting symptoms at first medical examination or follow-up were defined as symptomatic. Those with no symptoms at first examination or follow-up were defined as asymptomatic. Additional clinical data were available from the national anonymized patient-level electronic surveillance system (the Genitourinary Medicine Clinic Activity Dataset \[GUMCADv2\]), which records all tests and diagnoses in STI clinics in England ([@R12]).

PHE has authority to collect anonymized patient-level data for public health monitoring and infection control. The study was reviewed in PHE's research and development office and deemed to fit this criterion.

We used univariable and multivariable logistic regression modeling in STATA version 13.1 (StataCorp LP, College Station, TX, USA) to investigate risk factors associated with LGV versus non-LGV CT infection and asymptomatic versus symptomatic LGV. A clinic in Glasgow, Scotland, was excluded from risk factor analyses because it does not report GUMCADv2 ([Figure](#F1){ref-type="fig"}).
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During the study period, 921 eligible specimens were received for DNA typing. On confirmatory testing, 90 (10%) specimens were CT negative, 36 (4%) inhibitory, and 1 (0.1%) equivocal; 4 (0.4%) were not tested. CT infection was confirmed in 790 specimens from 713 patients; these specimens then underwent DNA typing. Overall, we found 69 (9%) LGV CT--positive specimens from 66 (9%) patients and 721 (91%) non-LGV CT--positive specimens from 647 (91%) patients ([Table 1](#T1){ref-type="table"}). Co-infection with LGV CT at 1 anatomic site and non-LGV CT at a different site was found in 4/713 (0.6%) patients. Clinical data coordinating with the symptom checklist and GUMCADv2 were available for 95% (680/713) and 87% (603/690) of CT-positive patients, respectively. During the study period, GUMCADv2 recorded 1,097 CT diagnoses among 10,143 MSM screened at the 11 STI clinics in England, showing an estimated CT prevalence of 10.8%.

###### Descriptive, univariable, and multivariable analysis of patients diagnosed with symptomatic versus nonsymptomatic LGV CT infection among men who have sex with men, by demographic and behavioral characteristics, United Kingdom\*

  ---------------------------------------------------- --------------------------- --------------- ---------------------- --------- ------------------------- --------- ---- --------------------- ---------
  Patient characteristics                              No. (%) or median \[IQR\]                   Univariable analysis             Multivariable analysis†                                        
  All CT                                               Non-LGV CT                  LGV CT          OR (95% CI)            p value   OR (95% CI)               p value                              
  All patients                                         713 (100)                   647 (90.7)      66 (9.3)               ND        ND                        ND        ND                         
  Clinic location, n = 713                                                                                                                                                                         
  London                                               563 (79.0)                  512 (79.1)      51 (77.3)                        1                         0.73                                 
  Manchester                                           85 (11.9)                   75 (11.6)       10 (15.2)                        1.34 (0.65--2.75)                                              
  Brighton                                             42 (5.9)                    38 (5.9)        4 (6.1)                          1.06 (0.36--3.08)                                              
  Glasgow‡                                             23 (3.2)                    22 (3.4)        1 (1.5)                                                                                         
  Infection site, n = 710                                                                                                                                                                          
  Nonrectal                                            221 (31.1)                  217 (33.7)      4 (6.1)                          1                                        1                     
  Rectal                                               489 (68.9)                  427 (66.3)      62 (93.9)                        7.83 (2.81--21.82)        \<0.001        10.08 (3.37--30.17)   \<0.001
  Multiple infection sites, n = 713                                                                                                                                                                
  No                                                   641 (89.9)                  581 (89.8)      60 (90.9)                        1                                                              
  Yes                                                  72 (10.1)                   66 (10.2)       6 (9.1)                          0.89 (0.37--2.15)         0.8                                  
  Symptoms present, n = 650                                                                                                                                                                        
  No                                                   453 (69.7)                  438 (73.6)      15 (27.3)                        1                                        1                     
  Yes                                                  197 (30.3)                  157 (26.4)      40 (72.7)                        7.93 (4.20--14.99)        \<0.001        13.33 (6.53--27.21)   \<0.001
  Age, y, n = 710                                      33 \[27--42\]               33 \[27--42\]   39 \[33--46\]                                                                                   
  18--24                                               108 (15.2)                  106 (16.5)      2 (3.0)                          1                         0.002                                
  25--34                                               276 (38.9)                  258 (40.1)      18 (27.3)                        3.72 (0.85--16.31)                                             
  35--44                                               192 (27.0)                  166 (25.8)      26 (39.4)                        7.92 (1.84--34.15)                                             
  [\>]{.ul}44                                          134 (18.9)                  114 (17.7)      20 (30.3)                        9.11 (2.08--39.93)                                             
  Ethnicity, n = 603                                                                                                                                                                               
  White                                                480 (79.6)                  432 (79.3)      48 (82.8)                        1                         0.17                                 
  Black or Black   British                             28 (4.6)                    27 (5)          1 (1.7)                          0.33 (0.44--2.51)                                              
  Mixed                                                27 (4.5)                    27 (5)          0                                NP                                                             
  Asian and Asian   British                            21 (3.5)                    21 (3.9)        0                                NP                                                             
  Other ethnic groups                                  23 (3.8)                    19 (3.5)        4 (6.9)                          1.89 (0.62--5.80)                                              
  Unknown                                              24 (4)                      19 (3.5)        5 (8.6)                          2.37 (0.85--6.63)                                              
  HIV status, n = 603                                                                                                                                                                              
  Negative                                             367 (60.9)                  350 (64.2)      17 (29.3)                        1                                        1                     
  Positive                                             236 (39.1)                  195 (35.8)      41 (70.7)                        4.33 (2.40--7.82)         \<0.001        3.63 (1.80--7.32)     \<0.001
  No. sexual partners in previous 3 mo, n = 635                                                                                                                                                    
  No. partners                                         3 \[1--5\]                  3 \[1--5\]      3 \[1--8\]                                                                                      
  0--1                                                 169 (26.6)                  153 (26.3)      16 (29.6)                        1                         0.26                                 
  2--5                                                 321 (50.6)                  299 (51.5)      22 (40.7)                        0.66 (0.34--1.31)                                              
  [\>]{.ul}6                                           145 (22.8)                  129 (22.2)      16 (29.6)                        1.13 (0.54--2.36)                                              
  Concurrent sexually transmitted infection, n = 631                                                                                                                                               
  No                                                   451 (71.5)                  406 (71)        45 (76.3)                        1                                                              
  Yes                                                  180 (28.5)                  166 (29)        14 (23.7)                        0.76 (0.41--1.42)         0.39                                 
  STI within previous 12 mo, n = 594                                                                                                                                                               
  No                                                   469 (79)                    435 (80.3)      34 (65.4)                        1                                                              
  Yes                                                  125 (21)                    107 (19.7)      18 (34.6)                        2.15 (1.17--3.96)         0.01                                 
  ---------------------------------------------------- --------------------------- --------------- ---------------------- --------- ------------------------- --------- ---- --------------------- ---------

\*n values indicate number of patients for which data were available in each category. CT, *Chlamydia trachomatis*; LGV, lymphogranuloma venereum; IQR, interquartile range; OR, odds ratio; ND, no data were available; NP, not performed. Blank cells indicate not applicable. †Multivariable analysis adjusted for age and location. ‡Glasgow patients were excluded from all univariable and multivariable analyses because they do not routinely report to the Genitourinary Medicine Clinic Activity Dataset.

Compared to those positive for non-LGV CT, patients with LGV CT infection were older and more likely to be symptomatic, to be HIV-positive, to have rectal infection, and to have had a previous STI diagnosis. In adjusted logistic regression analysis, symptomatic infection (adjusted odds ratio \[aOR\] 13.33; p\<0.001), rectal infection (aOR 10.08; p\<0.001) and being HIV-positive (aOR 3.63; p\<0.001) remained statistically significant ([Table 1](#T1){ref-type="table"}).

Of those with LGV for whom data were available, 27% (15/55) overall and 22% (12/54) with rectal-only infection were asymptomatic. Study prevalence of asymptomatic LGV was 2.3% (15/650) overall and 3.8% (9/236) in HIV-positive MSM ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

###### Descriptive, univariable and multivariable analysis of patients in whom asymptomatic LGV CT or asymptomatic non-LGV CT infection was diagnosed, by demographic and behavioral characteristics, United Kingdom\*

  Patient characteristics                               No. (%) or median \[IQR\]                                                                                           
  ----------------------------------------------------- --------------------------- --------------- --------------- --- -------------------- ------ -- -------------------- ------
  All patients                                          429 (100.0)                 414 (96.5)      15 (3.5)                                                                
  Clinic location, n = 429                                                                                                                                                  
  London                                                333 (77.6)                  323 (78.0)      10 (66.7)           1                    0.47                           
  Manchester                                            54 (12.6)                   52 (12.6)       2 (13.3)            1.24 (0.26--5.83)                                   
  Brighton                                              26 (6.1)                    24 (5.8)        2 (13.3)            2.69 (0.56--12.99)                                  
  Glasgow‡                                              16 (3.7)                    15 (3.6)        1 (6.7)                                                                 
  Infection site, n = 427                                                                                                                                                   
  Nonrectal                                             129 (30.2)                  126 (30.6)      3 (20.0)            1                                                   
  Rectal                                                298 (69.8)                  286 (69.4)      12 (80.0)           1.67 (0.46--6.08)    0.44                           
  Multiple infection sites, n = 429                                                                                                                                         
  No                                                    397 (92.5)                  383 (92.5)      14 (93.3)           1                                                   
  Yes                                                   32 (7.5)                    31 (7.5)        1 (6.7)             0.95 (0.12--7.48)    0.96                           
  Age, y, n = 429                                       33 \[27--42\]               33 \[26--42\]   38 \[29--44\]   ­                                                       
  18--24                                                73 (17.0)                   72 (17.4)       1 (6.7)             1                    0.64                           
  25--34                                                172 (40.1)                  167 (40.3)      5 (33.3)            2.19 (0.25--19.07)                                  
  35--44                                                105 (24.5)                  99 (23.9)       6 (40.0)            3.72 (0.43--32.59)                                  
  [\>]{.ul}44                                           79 (18.4)                   76 (18.4)       3 (20.0)            2.8 (0.28--27.55)                                   
  Ethnicity, n = 378                                                                                                                                                        
  White                                                 302 (79.9)                  290 (79.5)      12 (92.3)           1                    0.32                           
  Black or Black   British                              18 (4.8)                    18 (4.9)        0                   NP                                                  
  Mixed                                                 19 (5.0)                    19 (5.2)        0                   NP                                                  
  Asian and   Asian British                             17 (4.5)                    17 (4.7)        0                   NP                                                  
  Other ethnic   groups                                 13 (3.4)                    13 (3.6)        0                   NP                                                  
  Unknown                                               9 (2.4)                     8 (2.2)         1 (7.7)             3.02 (0.35--26.13)                                  
  HIV status, n = 378                                                                                                                                                       
  Negative                                              235 (62.2)                  231 (63.3)      4 (30.8)            1                                                   
  Positive                                              143 (37.8)                  134 (36.7)      9 (69.2)            3.88 (1.17--12.84)   0.03      3.91 (0.92--16.66)   0.06
  No. sexual partners in previous 3 mo, n = 401                                                                                                                             
  No. partners                                          3 \[1--5\]                  3 \[1--5\]      3 \[2--5\]                                                              
  0--1                                                  106 (26.4)                  103 (26.7)      3 (20.0)            1                    0.87                           
  2--5                                                  207 (51.6)                  198 (51.3)      9 (60.0)            1.41 (0.37--5.44)                                   
  [\>]{.ul}6                                            88 (21.9)                   85 (22.0)       3 (20.0)            1.16 (0.23--5.90)                                   
  Concurrent sexually transmitted infections, n = 398                                                                                                                       
  No                                                    295 (74.1)                  283 (73.7)      12 (85.7)           1                                                   
  Yes                                                   103 (25.9)                  101 (26.3)      2 (14.3)            0.47 (0.10--2.12)    0.32                           
  STI during previous 12 mo, n = 374                                                                                                                                        
  No                                                    297 (79.4)                  291 (80.4)      6 (50.0)            1                                                   
  Yes                                                   77 (20.6)                   71 (19.6)       6 (50.0)            4.1 (1.28--13.09)    0.02      3.1 (0.87--10.99)    0.08

\*n values indicate number of patients for which data were available in each category. CT, *Chlamydia* *trachomatis*; LGV, lymphogranuloma venereum; No., number; IQR, interquartile range; CI, confidence interval; OR, odds ratio; NP, not performed. Blank cells indicate not applicable. †Multivariable analysis adjusted for age and location ‡Glasgow patients were excluded from all univariable and multivariable analyses because they do not routinely report to the Genitourinary Medicine Clinic Activity Dataset.

Of the 15 patients with asymptomatic LGV, 12 (80%) had rectal, 2 (13%) urethral, and 1 (7%) pharyngeal infections. All cases of asymptomatic LGV were from patients with single-site infection.

Among asymptomatic patients, those with LGV were more likely to be HIV-positive (69% vs. 31%; odds ratio 3.88; p = 0.03) and to have had an STI in the past 12 months (50% vs. 20%; odds ratio 4.1; p = 0.02) than those infected with non-LGV CT. These characteristics were only weakly associated in the adjusted analysis (aOR 3.91, p = 0.06, and aOR 3.1, p = 0.08, respectively).

Conclusions
===========

This large multicenter case-finding study found a higher rate of asymptomatic LGV (27%) than previously reported in the United Kingdom, in agreement with studies done in Germany and the Netherlands. LGV case-patients were typically older, white, HIV-positive MSM who had a concurrent or recent STI diagnosis. Most infections were rectal; few urethral and pharyngeal infections were detected.

The number of CT infections confirmed at the reference laboratory (713) was lower than those reported to national surveillance (1,097), possibly related to differences in test sensitivity, degradation of CT DNA during transportation, or incorrect surveillance coding. No patients were excluded because of study restrictions; therefore, it is likely the study case-patients were representative of all MSM with diagnoses of CT infection in the United Kingdom.

More than one quarter of LGV cases in the United Kingdom may go undiagnosed if those who have asymptomatic chlamydial infection are not tested, as is the current strategy. Recommending that all CT-positive specimens from MSM be DNA tested for LGV serovars is unlikely to be cost-effective or feasible. However, because 3.8% of asymptomatic HIV-positive MSM had LGV (i.e., in excess of the recommended 3% prevalence threshold for CT screening \[[@R13]\]), inclusion of these patients in the testing algorithm, as is done in Scotland ([@R14])*,* may be warranted.

Whether LGV symptomatology in the United Kingdom has changed or asymptomatic cases were previously missed is unclear. Changes in screening practice or selection pressure for asymptomatic infection after treatment of persons with symptomatic infection may have contributed. Most asymptomatic patients will be treated for non-LGV CT infection, but if treatment is suboptimal, it may not prevent onward transmission ([@R15])*.*

An undiagnosed reservoir of CT infection is unlikely to be the sole cause of the current epidemic. High-risk sexual behavior remains a substantive challenge for control of LGV and related epidemics among MSM ([@R3]). Future public health strategies will require a combined strategy of increased testing, prompt treatment, and continued promotion of safer sexual behavior among MSM.

###### 

**Technical Appendix.** Symptom checklist posted on Public Health England site for detection of asymptomatic lymphogranuloma venereum infection in men who have sex with men.
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